The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes

Diabetic Medicine

Volumn 23, Issue 2, 2006, Pages 128-133

  Donnelly, L A ^a   Doney, A S F ^a   Hattersley, A T ^b   Morris, A D ^a   Pearson, E R ^a,b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Diabetes; Metformin; Obesity; Sulphonylureas

Indexed keywords

GLICLAZIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645076514     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01755.x     Document Type: Article

References (19)

1. The pharmacologic treatment of hyperglycaemia in NIDDM Diabetes Care 1996 19 Suppl. 1 553 561
2. McIntosh A Hutchinson A Home PD Brown F Bruce A Damerell A et al. 2001 Clinical Guidelines and Evidence Review for Type Diabetes: Management of Blood Glucose Sheffield ScHARR, University of Sheffield.
3. Johansen K. Efficacy of metformin in the treatment of NIDDM Diabetes Care 1999 22 33 37
4. DeFronzo RA Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group N Engl J Med 1995 333 541 549
5. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998 352 854 865
6. The American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management - 2000 update Endocr Pract 2000 6 43 84
7. DeFronzo RA Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 1999 131 281 303
8. Feinglos MN Bethel MA Oral agent therapy in the treatment of type 2 diabetes Diabetes Care 1999 22 C61 64
9. Hermann LS Schersten B Bitzen PO Kjellstrom T Lindgarde F Melander A. Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations. A double-blind controlled study Diabetes Care 1994 17 1100 1109
10. Hermann LS Schersten B Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination Diabet Med 1994 11 953 960
11. Altman DG Bland JM. Diagnostic tests 1 Sensitivity and specificity Br Med J 1994 308 1552
12. Morris AD Boyle DI MacAlpine R Emslie-Smith A Jung RT Newton RW et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration Br Med J 1997 315 524 528
13. Carstairs V Morris R. Deprivation and Health in Scotland Aberdeen Aberdeen University Press 1991
14. McLoone P. Carstairs Scores for Scottish Postcode Sectors from the 1991 Census Glasgow, Public Health Research Unit University of Glasgow 1994
15. UK Prospective Diabetes Study (UKPDS) Group. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years Br Med J 1995 310 83 88
16. Blaum CSL Velez Hiss RG Halter JB. Characteristics related to poor glycemic control in NIDDM patients in community practice Diabetes Care 1997 20 7 11
17. DeFronzo RA Barzilai N Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects J Clin Endocrinol Metab 1991 73 1294 1301
18. Jones TA Sautter M Van Gaal LF Jones NP Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes Diabetes Obes Metab 2003 5 163 170
19. Garber AJ Using dose-response characteristics of therapeutic agents for treatment decisions in type 2 diabetes Diabetes, Obesity Metabolism 2000 2 139